The stock of Agenus Inc (NASDAQ:AGEN) is a huge mover today! About 1.47 million shares traded hands or 2.80% up from the average. Agenus Inc (NASDAQ:AGEN) has risen 3.57% since April 27, 2016 and is uptrending. It has underperformed by 1.66% the S&P500.
The move comes after 9 months negative chart setup for the $350.38M company. It was reported on Nov, 30 by Barchart.com. We have $3.79 PT which if reached, will make NASDAQ:AGEN worth $28.03 million less.
Analysts await Agenus Inc (NASDAQ:AGEN) to report earnings on March, 2. They expect $-0.33 EPS, down 73.68% or $0.14 from last year’s $-0.19 per share. After $-0.47 actual EPS reported by Agenus Inc for the previous quarter, Wall Street now forecasts -29.79% EPS growth.
Agenus Inc (NASDAQ:AGEN) Ratings Coverage
Out of 5 analysts covering Agenus (NASDAQ:AGEN), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Agenus has been the topic of 8 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Maxim Group upgraded the shares of AGEN in a report on Friday, March 11 to “Buy” rating. The stock of Agenus Inc (NASDAQ:AGEN) has “Buy” rating given on Thursday, October 27 by Maxim Group. Jefferies initiated the stock with “Buy” rating in Wednesday, December 16 report. The rating was maintained by MLV on Monday, July 27 with “Buy”. The firm has “Neutral” rating by H.C. Wainwright given on Friday, October 28. The firm has “Hold” rating given on Tuesday, October 27 by Maxim Group. As per Friday, July 29, the company rating was maintained by Jefferies. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9.
According to Zacks Investment Research, “Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.93 in Q2 2016. Its up 1.13, from 0.8 in 2016Q1. The ratio improved, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
Natl Bank Of America De has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Amer International Group has 0% invested in the company for 42,074 shares. Spark Inv Limited Co last reported 0.04% of its portfolio in the stock. Pathstone Family Office Ltd Liability has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Fmr Ltd last reported 0% of its portfolio in the stock. Artal Group accumulated 0.08% or 1.00M shares. Blackrock Institutional Trust Na has 1.86 million shares for 0% of their US portfolio. Sei last reported 0% of its portfolio in the stock. State Street Corporation holds 0% or 1.16 million shares in its portfolio. Bruce & Company reported 233,515 shares or 0.24% of all its holdings. Vanguard last reported 0% of its portfolio in the stock. Millennium Mgmt Ltd Liability Company holds 0.03% or 2.95M shares in its portfolio. Creative Planning has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Credit Suisse Ag accumulated 0% or 41,045 shares. The New York-based Goldman Sachs Group has invested 0% in Agenus Inc (NASDAQ:AGEN).
Insider Transactions: Since September 6, 2016, the stock had 1 buying transaction, and 0 insider sales for $188,700 net activity. $188,700 worth of Agenus Inc (NASDAQ:AGEN) was bought by WIINBERG ULF on Tuesday, September 6.
More news for Agenus Inc (NASDAQ:AGEN) were recently published by: Fool.com, which released: “3 Red Flags on Agenus Inc’s Balance Sheet” on November 23, 2016. Prnewswire.com‘s article titled: “Agenus to Present at the Jefferies 2016 London Healthcare Conference” and published on November 14, 2016 is yet another important article.
AGEN Company Profile
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Firm is engaged in discovering and developing treatments for patients with cancer. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Firm has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP) vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Firm has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.